Omeros grants CEO 500,000-share performance stock option with $17.88 exercise price
On October 28, 2026, Omeros's Compensation Committee granted CEO Gregory A. Demopulos an option to buy up to 500,000 shares, vesting only if stock-price hurdles of $25.00 to $40.00 are met and he remains in service. The committee cited his 2025 achievements, including FDA approval of YARTEMLEA and the sale of zaltenibart to Novo, and said the award was set below peer-level long-term incentives. For shareholders, the award pays out only if the stock rises substantially, but any shares issued on exercise would dilute existing holders.
Key points
- Option covers up to 500,000 shares of common stock, with an exercise price of $17.88, the October 28, 2026 closing price
- Four tranches vest at 30-day volume-weighted average prices of $25.00, $30.00, $35.00 and $40.00, about 40%, 68%, 96% and 124% above the grant-date close
- Time condition: 25% of each tranche becomes eligible one year after grant, with the remainder vesting in monthly installments over the following 36 months
- Option expires October 28, 2031
The filing
Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 30, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.